Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty

Masato Tsutsui, Hiroaki Shimokawa, Seiji Higuchi, Shingo Yoshihara, Kiyoshi Hayashida, Atsushi Sobashima, Takeshi Kuga, Takeyuki Matsuguchi, Shuichi Okamatsu

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

The possible preventive effect of cilostazol, a novel anti-platelet drug, on restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) was examined. One hundred and two consecutive patients, who underwent successful PTCA, were followed for 3 to 6 months. To prevent restenosis, 46 patients (60 PTCA sites) were treated with cilostazol alone (200 mg/day) (cilostazol group) and the remaining 56 (61 PTCA sites) were treated with other anti-platelet drugs and/or warfarin potassium (control group). Restenosis was defined as a more than 50% loss of the initial gain of the coronary diameter achieved by PTCA. Cilostazol did not significantly reduce the patient or lesion restenosis rate; the patient restenosis rate was 32% in the control group and 22% in the cilostazol group (P=0.24), and the lesion restenosis rate was 30% in the control group and 23% in the cilostazol group (P=0.44). However, the lesion non-progression rate, which was defined as the incidence of lesions with either no change or regression of coronary stenosis at the PTCA site, was significantly greater with cilostazol (37%) than in the control group (16%) (p<0.05). Although cilostazol failed to show a significant reduction in restenosis after PTCA, the present results suggest that a further trial with a larger number of patients is needed to confirm its usefulness.

Original languageEnglish
Pages (from-to)207-215
Number of pages9
JournalJAPANESE CIRCULATION JOURNAL
Volume60
Issue number4
DOIs
Publication statusPublished - 1996 Apr

Keywords

  • Anti-platelet drug
  • Cilostazol
  • Percutaneous transluminal coronary angioplasty (PTCA)
  • Restenosis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty'. Together they form a unique fingerprint.

Cite this